跳至主要内容
临床试验/CTRI/2011/09/002015
CTRI/2011/09/002015已完成3 期

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Fibromyalgia (Protocol A0081245) - Not applicable

Pfizer Limited0 个研究点目标入组 290 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
290

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients must have fibromyalgia.

排除标准

  • Patients with other painful conditions cannot participate.

研究者

相似试验

进行中(未招募)
1 期
Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptomsOveractive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH)MedDRA version: 23.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857
EUCTR2018-003135-30-PTrovant Sciences GmbH1,088
进行中(未招募)
不适用
A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study ofthe Safety and Efficacy of Adefovir Dipivoxil in Children andAdolescents (Age 2 to <18) with Chronic Hepatitis B
EUCTR2004-001346-33-Outside-EU/EEAGilead Sciences Inc.173
招募中
3 期
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
CTRI/2011/07/001905Pfizer Limited800
进行中(未招募)
1 期
Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptomsOveractive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH)MedDRA version: 21.1 Level: LLT Classification code 10059617 Term: Overactive bladder System Organ Class: 100000004857
EUCTR2018-003135-30-ESrovant Sciences GmbH1,088
已完成
不适用
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus-E119 Non-insulin-dependent diabetes mellitus, without complications-I10 Essential (primary) hypertensionNon-insulin-dependent diabetes mellitus, without complicationsEssential (primary) hypertensionE119I10
PER-096-06TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,